These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 2508259

  • 1. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

  • 2. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 3. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 4. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM, Dosne AM, Kher A, Samama M.
    Thromb Haemost; 1989 Nov 24; 62(3):923-6. PubMed ID: 2556812
    [Abstract] [Full Text] [Related]

  • 5. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET, Mack DL, Sobel BE.
    Thromb Haemost; 1989 Nov 24; 62(3):909-16. PubMed ID: 2512679
    [Abstract] [Full Text] [Related]

  • 6. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M, Cavallo LG, Agnelli G, Mele A, Bürgi R, Heim J, Semeraro N.
    Thromb Haemost; 1993 May 03; 69(5):466-72. PubMed ID: 8391727
    [Abstract] [Full Text] [Related]

  • 7. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR, Nelles L, Van Hoef B, De Cock F, Collen D.
    Thromb Haemost; 1988 Oct 31; 60(2):247-50. PubMed ID: 3146141
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D, Stassen JM, De Cock F.
    Thromb Haemost; 1987 Oct 28; 58(3):943-6. PubMed ID: 3124288
    [Abstract] [Full Text] [Related]

  • 10. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT, Francis CW, Marder VJ.
    J Lab Clin Med; 1992 Jul 28; 120(1):120-8. PubMed ID: 1613318
    [Abstract] [Full Text] [Related]

  • 11. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B, Ries M, Zenker M, Rauh M, Beinder E, Keuper H, Harms D.
    Semin Thromb Hemost; 1998 Jul 28; 24(6):599-604. PubMed ID: 10066156
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 15. [New thrombolytic agents].
    Nguyen G, Samama M.
    Ann Biol Clin (Paris); 1987 Jun 30; 45(2):212-8. PubMed ID: 3113300
    [Abstract] [Full Text] [Related]

  • 16. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.
    Sabovic M, Lijnen HR, Keber D, Collen D.
    Thromb Haemost; 1990 Nov 30; 64(3):450-4. PubMed ID: 2096491
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
    Stassen JM, Juhan-Vague I, Alessi MC, De Cock F, Collen D.
    Thromb Haemost; 1987 Oct 28; 58(3):947-50. PubMed ID: 2829381
    [Abstract] [Full Text] [Related]

  • 19. Role of alpha 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma.
    Declerck PJ, Lijnen HR, Verstreken M, Collen D.
    Thromb Haemost; 1991 Apr 08; 65(4):394-8. PubMed ID: 2057921
    [Abstract] [Full Text] [Related]

  • 20. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI, Leslie B, Ginsberg J.
    J Clin Invest; 1991 Mar 08; 87(3):1082-90. PubMed ID: 1900308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.